March 4, 2025 · Form 4 insider transaction
Reardon Andrew bought 6,415 shares of Ligand Pharmaceuticals Incorporated at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2026; February 15, 2027; and February 15, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date.